Product Code: 137425-08-22
Metabolomics is a novel, emerging and dynamic field that studies metabolites, a distinctive chemical fingerprints produced during cellular process. Thus it identifies and quantifies metabolites further with the help of analytical technologies and application of bioinformatics extract information and analyze the same. Metabolomics though currently at nascent stage, will be widely used in biopharma and biotech industry as biomarker drug development and information. Being non-invasive in nature and closely linked to phenotype, it is an ideal tool used in agricultural industries, pharmaceutical and preventive healthcare. Rise in the number of clinical trials, awareness about nutritional products, toxicological testing data, rapid growth of metabolomics data analysis software and solutions is expected to propel the growth of this market.
The report titled "Metabolomics market - Growth, Future Prospects and Competitive Analysis, 2022-2030" offers strategic insights into the overall metabolomics market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of product and services, application, indication and different geographies. The product and services type segment studied for analyzing the overall global metabolomics market is majorly segmented into metabolomics instruments and metabolomics bioinformatics tools and services. Metabolomics instruments is sub-segmented into separation tools and detection tools. Separation tools include high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography and capillary electrophoresis. Detection tools comprise mass spectrometry, nuclear magnetic resonance spectroscopy and surface-based mass analysis. Metabolomics bioinformatics tools and services category is sub-segmented into bioinformatics tools & databases, and bioinformatics services. The global metabolomics market is segmented by application type into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine and others. Based on indications, this market is categorized into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism and others.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global metabolomics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global metabolomics market. This report concludes with company profiles section that highlights major information about the key players engaged in global metabolomics market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.
Metabolomics instrument occupies the largest share of global metabolomics market. Metabolomics bioinformatics tools and services is fast growing segment during the forecast period. With further technological developments, bioinformatics tools have enhanced the untargeted metabolomics workflow, enabling researchers to identify metabolite from LC/MS data and assign their biological roles with respect to chemical pathways. In separation tools segments, High-performance liquid chromatography dominates the market. While ultra-performance liquid chromatography provides high efficiency and high resolution chromatographic separation, with reduction in analysis time, hence anticipated to be fast growing market in future. Detection tool segment, mass spectrometry occupies the maximum share, with nuclear magnetic resonance spectroscopy showing fast adaptability and bright future market growth.
Biomarker discovery occupies the largest share of the global metabolomics market. Metabolomics techniques aid in discovering the potential biomarkers and providing insight into pathogeneses of numerous human diseases. With advancement in analytical technology, it possible to quantify the biomarkers from small amount of specimens using minimally invasive or non-invasive procedure, to facilitate high throughput analysis for real time application in clinical setting. Drug discovery is next followed up market for metabolomics. Metabolomics helps in diagnosing the disease by understanding the biochemical pathway, thus further aiding in drug identification, designing and customization according therapeutic needs. Personalized medicine is anticipated to be the fastest growing segment during the forecast period with biotech and pharma companies investing heavily in it research and development.
Cancer dominates the global metabolomics market by indication segmentation. Cancer study through metabolomics helps in revealing new biomarkers for cancer which would help in future diagnosis, prognosis and therapy. Cardiovascular chronic disease is the greatest public health burden globally. Thus use of metabolomic profiling would help to identify new biomarkers and mechanisms of CVD risk. Current clinical diagnosis of neurological diseases such as Parkinson's and Alzheimer diseases on basis of clinical criteria is unsatisfactory, so emerging metabolomics techniques help in discovering in now biomarker and biochemical pathway for improving the future diagnosis and determination of prognosis therapy.
North America dominates the global metabolomics market followed by Europe. The key drivers are surge in research and development funding by government and private players for metabolomics studies, rising demand for personalized medicine and toxicology testing, easy accessibility of technologically advanced products and its high adoption rate, presence of various metabolomics manufactures. Growing demand for the personalized medicine, large presence of the analytical equipment manufacturers in Europe contribute to the growth of metabolomics market. Asia Pacific has significant growth opportunity for the metabolomics market due to presence of number of pharmaceutical and biotechnology companies and its initiatives in research and development, improving health care infrastructure, emerging economies such as China, Japan, India and Singapore.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Metabolomics market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Metabolomics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Product and Services
Metabolomic Instruments
Separation Tools
Gas Chromatography
Ultra-Performance Liquid Chromatography
Capillary Electrophoresis
Detection Tools
Mass Spectrometry
Nuclear Magnetic Resonance Spectroscopy
Surface-Based Mass Analysis
Metabolomics Bioinformatics Tools and Services
Bioinformatics Tools & Databases
Bioinformatics Services
Application
Biomarker Discovery
Drug Discovery
Functional Genomics
Personalized Medicine
Toxicology Testing
Nutrigenomics
Others
Indication
Cancer
Cardiovascular Disorders
Neurological Disorders
Inborn Errors of Metabolism
Others
Region Segment (2020-2030; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Million )
Pre Covid-19 situation
Post Covid-19 situation
Key questions answered in this report
What are the key micro and macro environmental factors that are impacting the growth of Metabolomics market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2030.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Metabolomics market?
Which is the largest regional market for Metabolomics market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Metabolomics market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Metabolomics market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Metabolomics Market
- 2.2. Global Metabolomics Market, By Product and Services, 2021 (US$ Million)
- 2.3. Global Metabolomics Market, By Application, 2021 (US$ Million)
- 2.4. Global Metabolomics Market, By Indication, 2021 (US$ Million)
- 2.5. Global Metabolomics Market, By Geography, 2021 (US$ Million)
- 2.6. Attractive Investment Proposition by Geography, 2021
3. Metabolomics Market: Competitive Analysis
- 3.1. Market Positioning of Key Metabolomics Market Vendors
- 3.2. Strategies Adopted by Metabolomics Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2021 Versus 2030
4. Metabolomics Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Metabolomics Market Value, 2020 - 2030, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2021 Versus 2030
- 5.3. Market Segmentation
- 5.3.1. Metabolomic Instruments
- 5.3.1.1. Separation Tools
- 5.3.1.1.1. Gas Chromatography
- 5.3.1.1.2. Ultra-Performance Liquid Chromatography
- 5.3.1.1.3. Capillary Electrophoresis
- 5.3.1.2. Detection Tools
- 5.3.1.2.1. Mass Spectrometry
- 5.3.1.2.2. Nuclear Magnetic Resonance Spectroscopy
- 5.3.1.2.3. Surface-Based Mass Analysis
- 5.3.2. Metabolomics Bioinformatics Tools and Services
- 5.3.2.1. Bioinformatics Tools & Databases
- 5.3.2.2. Bioinformatics Services
6. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2021 Versus 2030
- 6.3. Market Segmentation
- 6.3.1. Biomarker Discovery
- 6.3.2. Drug Discovery
- 6.3.3. Functional Genomics
- 6.3.4. Personalized Medicine
- 6.3.5. Toxicology Testing
- 6.3.6. Nutrigenomics
- 6.3.7. Others
7. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2021 Versus 2030
- 7.3. Market Segmentation
- 7.3.1. Cancer
- 7.3.2. Cardiovascular Disorders
- 7.3.3. Neurological Disorders
- 7.3.4. Inborn Errors of Metabolism
- 7.3.5. Others
8. North America Metabolomics Market, 2020-2030, USD (Million)
- 8.1. Market Overview
- 8.2. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 8.3. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 8.4. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 8.5.Metabolomics Market: By Region, 2020-2030, USD (Million)
- 8.5.1.North America
- 8.5.1.1. U.S.
- 8.5.1.1.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 8.5.1.1.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 8.5.1.1.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 8.5.1.2. Canada
- 8.5.1.2.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 8.5.1.2.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 8.5.1.2.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 8.5.1.3. Rest of North America
- 8.5.1.3.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 8.5.1.3.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 8.5.1.3.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
9. UK and European Union Metabolomics Market, 2020-2030, USD (Million)
- 9.1. Market Overview
- 9.2. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.3. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.4. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.Metabolomics Market: By Region, 2020-2030, USD (Million)
- 9.5.1.UK and European Union
- 9.5.1.1. UK
- 9.5.1.1.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.1.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.1.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.1.2. Germany
- 9.5.1.2.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.2.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.2.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.1.3. Spain
- 9.5.1.3.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.3.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.3.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.1.4. Italy
- 9.5.1.4.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.4.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.4.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.1.5. France
- 9.5.1.5.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.5.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.5.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 9.5.1.6. Rest of Europe
- 9.5.1.6.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 9.5.1.6.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 9.5.1.6.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
10. Asia Pacific Metabolomics Market, 2020-2030, USD (Million)
- 10.1. Market Overview
- 10.2. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.3. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.4. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.Metabolomics Market: By Region, 2020-2030, USD (Million)
- 10.5.1.Asia Pacific
- 10.5.1.1. China
- 10.5.1.1.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.1.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.1.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.1.2. Japan
- 10.5.1.2.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.2.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.2.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.1.3. India
- 10.5.1.3.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.3.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.3.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.1.4. Australia
- 10.5.1.4.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.4.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.4.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.1.5. South Korea
- 10.5.1.5.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.5.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.5.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 10.5.1.6. Rest of Asia Pacific
- 10.5.1.6.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 10.5.1.6.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 10.5.1.6.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
11. Latin America Metabolomics Market, 2020-2030, USD (Million)
- 11.1. Market Overview
- 11.2. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 11.3. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 11.4. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 11.5.Metabolomics Market: By Region, 2020-2030, USD (Million)
- 11.5.1.Latin America
- 11.5.1.1. Brazil
- 11.5.1.1.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 11.5.1.1.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 11.5.1.1.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 11.5.1.2. Mexico
- 11.5.1.2.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 11.5.1.2.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 11.5.1.2.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 11.5.1.3. Rest of Latin America
- 11.5.1.3.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 11.5.1.3.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 11.5.1.3.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
12. Middle East and Africa Metabolomics Market, 2020-2030, USD (Million)
- 12.1. Market Overview
- 12.2. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 12.3. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 12.4. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 12.5.Metabolomics Market: By Region, 2020-2030, USD (Million)
- 12.5.1.Middle East and Africa
- 12.5.1.1. GCC
- 12.5.1.1.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 12.5.1.1.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 12.5.1.1.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 12.5.1.2. Africa
- 12.5.1.2.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 12.5.1.2.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 12.5.1.2.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
- 12.5.1.3. Rest of Middle East and Africa
- 12.5.1.3.1. Metabolomics Market: By Product and Services, 2020-2030, USD (Million)
- 12.5.1.3.1. Metabolomics Market: By Application, 2020-2030, USD (Million)
- 12.5.1.3.1. Metabolomics Market: By Indication, 2020-2030, USD (Million)
13. Company Profile
- 13.1. Agilent Technologies, Inc.
- 13.1.1. Company Overview
- 13.1.2. Financial Performance
- 13.1.3. Product Portfolio
- 13.1.4. Strategic Initiatives
- 13.2. Acureomics AB
- 13.2.1. Company Overview
- 13.2.2. Financial Performance
- 13.2.3. Product Portfolio
- 13.2.4. Strategic Initiatives
- 13.3. Amatsi Group
- 13.3.1. Company Overview
- 13.3.2. Financial Performance
- 13.3.3. Product Portfolio
- 13.3.4. Strategic Initiatives
- 13.4. Bayer, Inc.
- 13.4.1. Company Overview
- 13.4.2. Financial Performance
- 13.4.3. Product Portfolio
- 13.4.4. Strategic Initiatives
- 13.5. Berg LLC
- 13.5.1. Company Overview
- 13.5.2. Financial Performance
- 13.5.3. Product Portfolio
- 13.5.4. Strategic Initiatives
- 13.6. Biocrates Life Sciences AG
- 13.6.1. Company Overview
- 13.6.2. Financial Performance
- 13.6.3. Product Portfolio
- 13.6.4. Strategic Initiatives
- 13.7. Bio-Rad Laboratories, Inc.
- 13.7.1. Company Overview
- 13.7.2. Financial Performance
- 13.7.3. Product Portfolio
- 13.7.4. Strategic Initiatives
- 13.8. Bruker Corporation
- 13.8.1. Company Overview
- 13.8.2. Financial Performance
- 13.8.3. Product Portfolio
- 13.8.4. Strategic Initiatives
- 13.9. Chenomx,Inc
- 13.9.1. Company Overview
- 13.9.2. Financial Performance
- 13.9.3. Product Portfolio
- 13.9.4. Strategic Initiatives
- 13.10. Danher Corporation
- 13.10.1. Company Overview
- 13.10.2. Financial Performance
- 13.10.3. Product Portfolio
- 13.10.4. Strategic Initiatives
- 13.11. Human Metabolome Technologies, Inc.
- 13.11.1. Company Overview
- 13.11.2. Financial Performance
- 13.11.3. Product Portfolio
- 13.11.4. Strategic Initiatives
- 13.12. HepatoChem, Inc.
- 13.12.1. Company Overview
- 13.12.2. Financial Performance
- 13.12.3. Product Portfolio
- 13.12.4. Strategic Initiatives
- 13.13. IROA Technologies
- 13.13.1. Company Overview
- 13.13.2. Financial Performance
- 13.13.3. Product Portfolio
- 13.13.4. Strategic Initiatives
- 13.14. Leco Corporation
- 13.14.1. Company Overview
- 13.14.2. Financial Performance
- 13.14.3. Product Portfolio
- 13.14.4. Strategic Initiatives
- 13.15. Metabolon, Inc.
- 13.15.1. Company Overview
- 13.15.2. Financial Performance
- 13.15.3. Product Portfolio
- 13.15.4. Strategic Initiatives
- 13.16. Max Planck Society
- 13.16.1. Company Overview
- 13.16.2. Financial Performance
- 13.16.3. Product Portfolio
- 13.16.4. Strategic Initiatives
- 13.17. Metabolomic Discoveries GmbH
- 13.17.1. Company Overview
- 13.17.2. Financial Performance
- 13.17.3. Product Portfolio
- 13.17.4. Strategic Initiatives
- 13.18. Metabolomx
- 13.18.1. Company Overview
- 13.18.2. Financial Performance
- 13.18.3. Product Portfolio
- 13.18.4. Strategic Initiatives
- 13.19. Metabometrix Ltd.
- 13.19.1. Company Overview
- 13.19.2. Financial Performance
- 13.19.3. Product Portfolio
- 13.19.4. Strategic Initiatives
- 13.20. Metanomics GmbH
- 13.20.1. Company Overview
- 13.20.2. Financial Performance
- 13.20.3. Product Portfolio
- 13.20.4. Strategic Initiatives
- 13.21. Phenomenome Discoveries, Inc.
- 13.21.1. Company Overview
- 13.21.2. Financial Performance
- 13.21.3. Product Portfolio
- 13.21.4. Strategic Initiatives
- 13.22. SCIEX
- 13.22.1. Company Overview
- 13.22.2. Financial Performance
- 13.22.3. Product Portfolio
- 13.22.4. Strategic Initiatives
- 13.23. Shimadzu Corporation
- 13.23.1. Company Overview
- 13.23.2. Financial Performance
- 13.23.3. Product Portfolio
- 13.23.4. Strategic Initiatives
- 13.24. SiDMAP
- 13.24.1. Company Overview
- 13.24.2. Financial Performance
- 13.24.3. Product Portfolio
- 13.24.4. Strategic Initiatives
- 13.25. Stemina Biomarker Discovery, Inc
- 13.25.1. Company Overview
- 13.25.2. Financial Performance
- 13.25.3. Product Portfolio
- 13.25.4. Strategic Initiatives
- 13.26. Thermo Fisher Scientific, Inc.
- 13.26.1. Company Overview
- 13.26.2. Financial Performance
- 13.26.3. Product Portfolio
- 13.26.4. Strategic Initiatives
- 13.27. Waters Corporation
- 13.27.1. Company Overview
- 13.27.2. Financial Performance
- 13.27.3. Product Portfolio
- 13.27.4. Strategic Initiatives
- 13.28. Xceleron, Inc.
- 13.28.1. Company Overview
- 13.28.2. Financial Performance
- 13.28.3. Product Portfolio
- 13.28.4. Strategic Initiatives
- 13.29. Other Notable Players
- 13.29.1. Company Overview
- 13.29.2. Financial Performance
- 13.29.3. Product Portfolio
- 13.29.4. Strategic Initiatives